Cargando…

Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’

Detalles Bibliográficos
Autores principales:	Schaffalitzky de Muckadell, Philip, Strom, Claes Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475518/ https://www.ncbi.nlm.nih.gov/pubmed/30937852 http://dx.doi.org/10.1007/s40264-019-00814-5

Ejemplares similares

Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
por: Ehlken, Birgit, et al.
Publicado: (2018)

Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017”
por: Ehlken, Birgit, et al.
Publicado: (2019)

Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007–2018
por: Popiołek, Iwona, et al.
Publicado: (2019)

Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017)

An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance
por: Pinheiro, Luis C., et al.
Publicado: (2017)

Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database
por: Gamboa, Lorea, et al.
Publicado: (2023)

VigiAccess: Promoting public access to VigiBase
por: Shankar, Pathiyil Ravi
Publicado: (2016)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2023)

EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection
por: Postigo, Rodrigo, et al.
Publicado: (2018)

Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives
por: Sardella, Marco, et al.
Publicado: (2019)

Exploratory Study of Signals for Asthma Drugs in Children, Using the EudraVigilance Database of Spontaneous Reports
por: Baan, Esmé J., et al.
Publicado: (2019)

The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions
por: Candore, Gianmario, et al.
Publicado: (2021)

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database
por: Rastogi, Shruti, et al.
Publicado: (2022)

Post-Marketing Surveillance of Statins—A Descriptive Analysis of Psychiatric Adverse Reactions in EudraVigilance
por: Pop, Gabriela, et al.
Publicado: (2022)

Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
por: Nikitina, Victoria, et al.
Publicado: (2023)

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Pollock, Richard F., et al.
Publicado: (2019)

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Aksan, Ayşegül, et al.
Publicado: (2019)

Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
por: Correia Pinheiro, Luis, et al.
Publicado: (2021)

Suspected oncologic adverse reactions associated with interleukin‐23 inhibitors in EudraVigilance: Comparative study and gender distribution
por: Calapai, Fabrizio, et al.
Publicado: (2023)

A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database
por: Morgovan, Claudiu, et al.
Publicado: (2023)

Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance
por: Maltezou, Helena C., et al.
Publicado: (2023)

Safety profile of hydroxychloroquine used off‐label for the treatment of patients with COVID‐19: A descriptive study based on EudraVigilance data
por: Motola, Domenico, et al.
Publicado: (2022)

Does additional monitoring status increase the reporting of adverse drug reactions? An interrupted time series analysis of EudraVigilance data
por: Segec, Andrej, et al.
Publicado: (2020)

Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
por: Abbattista, Maria, et al.
Publicado: (2021)

Hypernatremia During Intravenous Treatment With Fosfomycin: A Retrospective Medical Record Review Study and an Analysis of Spontaneous Reports in the EudraVigilance Database
por: Scavone, Cristina, et al.
Publicado: (2022)

Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
por: Sportiello, Liberata, et al.
Publicado: (2023)

Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase(®)
por: Vogel, Ulrich, et al.
Publicado: (2020)

Characteristics and completeness of spontaneous reports by reporter's role in Germany: An analysis of the EudraVigilance database using the example of opioid‐associated abuse, dependence, or withdrawal
por: Jobski, Kathrin, et al.
Publicado: (2023)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

Montelukast and Nightmares: Further Characterisation Using Data from VigiBase
por: Watson, Sarah, et al.
Publicado: (2022)

Infections associated with clozapine: a pharmacovigilance study using VigiBase(®)
por: Chrétien, Basile, et al.
Publicado: (2023)

Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database
por: Tobaiqy, Mansour, et al.
Publicado: (2021)

Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
por: Park, Sunny, et al.
Publicado: (2021)

Short communication: Comments on hair disorders associated with dupilumab based on VigiBase
por: Park, Sunny, et al.
Publicado: (2022)

Comment on ‘Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9q6blnto3ld95fkvr59g74jem6